Jiangsu Hengrui Pharmaceuticals (600276.SH): Liposomal Idarubicin Hydrochloride Injection (II) approved for clinical trials.

Jiangsu Hengrui Pharmaceuticals(600276.SH) announced that its subsidiary, Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd., has recently received approval from the National Medical Products Administration to conduct clinical trials for the liposomal injection of Irinotecan Hydrochloride (). The clinical trials will begin in the near future. According to the Drug Administration Law of the People's Republic of China and relevant regulations, after review, the clinical trial application for Irinotecan Hydrochloride () liposomal injection, submitted on December 25, 2025, meets the requirements for drug registration, and permission has been granted to conduct this clinical trial. Specifically, the study is a randomized, open-label, parallel-controlled, multicenter Phase III clinical trial comparing the combination of HR070803 with Oxaliplatin, 5-Fluorouracil, and Calcium Folinate with Gemcitabine combined with Capecitabine for the adjuvant treatment of pancreatic cancer.